Shou Cheng Zhang

Nest.Bio Ventures (Nest.Bio) is a venture capital firm founded in 2017. The firm is headquartered in Cambridge, Massachusetts.

Goodman Capital Ltd (Goodman Capital) is an independent venture capital firm founded in 2013 by Jeffrey Lu and Daphne Teo. The firm is headquartered in Singapore.

KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA.

China Life Sciences Access Fund LP is a venture capital fund that operates in the life sciences industry. The private company is based in George Town, Cayman Islands.

Neusoft Medical Systems Co., Ltd. engages in the research, development, manufacturing, and sale of large-scale medical diagnosis and treatment equipment and solutions as well as the provision of related services. Its products include computed tomography systems, magnetic resonance imaging systems, digital subtraction angiography systems, ultrasonic diagnostic equipment, positron emission tomography equipment, radiotherapy products, as well as in vitro diagnostic equipment and reagents. The company was founded on March 6, 1998 and is headquartered in Shenyang, China.

Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. engages in research and development of medical technology. The company was founded by Zhi Hong on April 19, 2018 and is headquartered in Shanghai, China.

Part of Cutia Therapeutics, Cutia Therapeutics (Shanghai) Co., Ltd. develops therapeutics to treat severe facial acne vulgaris. The company is based in Shanghai, China. The Chinese company was founded in 2019. The CEO is Le Le Zhang.

Tongrun Biomedicine (Shanghai) Co., Ltd. develops tumor immunotherapy drugs. The company is based in Shanghai, China.

Uni Global Power Pte Ltd. operates as an investment holding company specializing in property development in emerging and frontier markets. It operates through offices including Hong Kong, China and Myanmar. The company was founded by Xiao Lin Zhu and is headquartered in Singapore.

Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then.

Enleofen Bio Pte Ltd. provides health care services for fibrotic diseases. It offers Cytokine Antibody, Receptor Antibody, Decoy Receptor and siRNA. The company was founded by Stuart Cook and Sebastian Schafer and is headquartered in Singapore.

PAIRx Bio Pte Ltd is a Singaporean company that is developing next generation cancer immunotherapies targeting shared tumour-associated antigens derived from aberrantly spliced proteins. The private company is based in Singapore, Singapore. The company's proprietary antigen and T cell validation methods yield simultaneous validation of tumour antigen-T cell pairs in multiple patient-derived tumours. The technology was developed at Duke-NUS Medical School in Prof David Epstein's lab, and the company was incubated by EVX Ventures and spun out from Duke-NUS. The founding investors are EVX Ventures and Avendesora. The company was founded by Raymond Lee, David Epstein, Xiang Qian Lin.

Think Big Analytics, Inc. provides big data and advanced analytics consulting services. It offers device data analytics, consumer insight, big data warehouse and analytics laboratory services. The firm serves the advertising, mobile and social networking, financial services, software and hardware IT, and healthcare sectors. The company was founded by Ronald Jeffrey Bodkin, Rick Anthony Farnell and Katie Bodkin in 2010 and is headquartered in Mountain View, CA.

Danhua Capital Management LLC (Danhua Capital Management) is a venture capital firm founded in 2013 by Andrew Gu. The firm is headquartered in Palo Alto, California.

Camford Capital Management LLC (Camford Capital) is a venture capital firm founded in 2013. The firm is headquartered in Menlo Park, California.

Sliver VR Technologies, Inc. is a next-generation eSports entertainment platform. The company was founded by Mitch Liu and Jieyi Long and is headquartered in Cupertino, CA.

Hangzhou Nuowei Information Technology Co., Ltd. provides a big data privacy computing platform and computing services. The company is based in Hangzhou, China. The Chinese company was founded in 2012 by Hao Zhang, Shuang Wang. Hao Zhang has been the CEO since 2012.

Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA.

Provectus Algae Pty Ltd. operates as a biotech company specialising in the optimisation of Algae to produce high-value compounds for a broad range of industries and applications. It offers natural and biosynthetic production services in antibiotics, vaccines, enzymes, cosmetics, hormones, terpenes, cannabinoids products.. The company was founded by Nusqe Spanton in 2018 and is headquartered in Noosaville, Australia.

Corvium, Inc. engages in the development of fist synthetic biology-based bacterial monitoring platform. Its product include Control-Pro, an EMP automation software that converts data into action. The company was founded by Bob Langer, Timothy Lu, Michael Koeris, Brett Chevalier, Micah Rosenbloom, Tanguy Chau, and James J. Collins in March 2009 and is headquartered in Woburnc, MA.

Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA.

Eligo Bioscience SA operates a micobiome engineering laboratory. The company uses synthetic biology and CRISPR and CAS technology to develop highly precise antimicrobials. The firm?s sequence-specific antimicrobials can therefore discriminate between close bacterial strains and selectively eradicate harmful bacteria from the microbiome while sparing the beneficial ones. The company was founded by Timothy Lu, Luciano Marraffini, David Bikard and Xavier Duportet in May 2014 and is headquartered in Paris, France.

Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA.

BiomX Ltd. engages in the development of customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease and colorectalcancer, as well as bacteria that affect the appearance of the skin. The company was founded by Eran Elinav, Timothy K. Lu, and Rotem Sorek on March 3, 2015 and is headquartered in Ness Ziona, Israel.

Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.